Claims for Patent: 9,700,530

Summary for Patent: 9,700,530

Title:	Capsule dosage form of metoprolol succinate
Abstract:	This disclosure provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units, wherein said capsule dosage form is bioequivalent to the marketed Toprol-XL.RTM. tablet. The extended-release capsule dosage form comprising coated discrete units can be sprinkled onto food to ease administration to patients who have difficulty swallowing tablets or capsules.
Inventor(s):	Vats; Sandeep Kumar (Sonipat, IN), Mondal; Balaram (East Midnapore, IN), Ramaraju; Kalaiselvan (Tiruchirappalli, IN), Singh; Romi Barat (Benares, IN)
Assignee:	SUN PHARMACEUTICAL INDUSTRIES LIMITED (Mumbai, IN)
Application Number:	15/337,611
Patent Claims:	1. An extended-release capsule dosage form of metoprolol succinate comprising coated discrete units having a d.sub.90 value between about 0.2 mm and 1.5 mm, wherein the coated discrete units, after dispersing in an aqueous media for at least 10 minutes, have a desired flowability when passed through a feeding tube and contain not more than 0.50% by weight of the related substances of metoprolol succinate. 2. The extended-release capsule dosage form according to claim 1, wherein the coated discrete units have d.sub.90 value from about 0.2 mm to 1.2 mm. 3. The extended-release capsule dosage form according to claim 1, wherein the particle size of the coated discrete units does not change more than 30% when exposed to an aqueous media for at least 10 minutes. 4. An extended-release capsule dosage form of metoprolol succinate comprising coated discrete units have d.sub.90 value between about 0.2 mm to 1.2 mm, wherein the coated discrete units when dispersed in aqueous media and delivered through a feeding tube having size NLT 10 F, at least 85% of metoprolol succinate is recovered at the exit of feeding tube after holding for at least 10 minutes. 5. The extended-release capsule dosage form according to claim 1, wherein the coated discrete units are in the form of a plurality of pellets, granules, minitablets, or beads. 6. The extended-release capsule dosage form according to claim 1, wherein the coated discrete units are lubricated before filling into the capsule. 7. The extended-release capsule dosage form according to claim 6, wherein the lubricant is selected from the group consisting of colloidal silicon dioxide, stearic acid, magnesium stearate, calcium stearate, talc, hydrogenated castor oil, sucrose esters of fatty acid, microcrystalline wax, yellow beeswax, white beeswax, and mixtures thereof. 8. The extended-release capsule dosage form according to claim 1, wherein the coated discrete units are administered by a feeding tube selected from the group consisting of NG tube, G tube, and J tube. 9. The extended-release capsule dosage form according to claim 8, wherein the coated discrete units are dispersed in an aqueous media in a latex-free syringe and subsequently delivered through a feeding tube. 10. An extended-release capsule dosage form of metoprolol succinate comprising coated discrete units having a d.sub.90 value between about 0.2 mm and 1.5 mm, wherein the coated discrete units, when sprinkled on soft foods having different pH levels and exposed for at least 30 minutes, contain not more than 0.50% by weight of the total related substances of metoprolol succinate. 11. An extended-release capsule dosage form of metoprolol succinate comprising coated discrete units having a d.sub.90 value between about 0.2 mm and 1.5 mm, which, when sprinkled onto soft foods, produces a dissolution profile of metoprolol succinate similar before and after exposure for at least 30 minutes to soft foods having different pH levels. 12. The extended-release capsule dosage form according to claim 4, wherein the coated discrete units are in the form of a plurality of pellets, granules, minitablets, or beads. 13. The extended-release capsule dosage form according to claim 4, wherein the coated discrete units are lubricated before filling into the capsule. 14. The extended-release capsule dosage form according to claim 4, wherein the coated discrete units are administered by a feeding tube selected from the group consisting of NG tube, G tube, and J tube.